Want to see DE:AAQ1 full AI Analyst Report?
AAQ1 Stock Chart & Stats
€1.26
€0.04(2.41%)
At close: 4:00 PM EST
€1.26
€0.04(2.41%)
Day’s Range― - ―
52-Week Range€1.26 - €2.34
Previous CloseN/A
Volume2.73K
Average Volume (3M)620.00
Market Cap
€23.11M
Enterprise Value€27.65M
Total Cash (Recent Filing)€1.40M
Total Debt (Recent Filing)€984.00K
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.20
Shares Outstanding14,716,976
10 Day Avg. Volume259
30 Day Avg. Volume620
Financial Highlights & Ratios
PEG Ratio0.15
Price to Book (P/B)2.27
Price to Sales (P/S)1.58
P/FCF Ratio-9.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue MomentumSustained top-line growth into 2025 indicates expanding product adoption and market penetration for implant systems. Durable revenue momentum supports scale, distribution leverage and investment in R&D or commercial expansion, increasing the probability of eventual operating leverage if maintained.
High Gross MarginsConsistently high gross margins reflect product-level pricing power and favorable manufacturing economics in implant lines. Durable margin advantage gives room to absorb SG&A, fund development, and drive operating profitability as fixed costs are spread with higher volumes or efficiency gains.
Improved Leverage / Balance SheetReduced debt and a sizable equity base materially lower financial distress risk and interest burden. A stronger balance sheet extends runway, enables selective investment or partnership deals, and reduces need for near-term emergency financing while management addresses profitability and cash generation.
Bears Say
Structural UnprofitabilityPersistent operating and net losses show the business has not yet converted revenue and gross margins into positive operating economics. Over months this limits retained earnings, pressures investor support, and requires either sustained external funding or rapid margin improvement to become self-sustaining.
Negative Cash GenerationConsistent negative operating and free cash flow indicate ongoing cash burn despite revenue gains. This constrains capital allocation, may force dilutive equity raises or debt, and reduces strategic flexibility to invest in commercialization or product development over the next several quarters.
Lack Of Operating LeverageDespite revenue growth and healthy gross margins, the company has not demonstrated operating leverage; costs scale with revenue or remain too high. Over time this impairs margin expansion prospects and slows progress toward sustainable profitability unless cost structure is rebalanced.
AAQ1 FAQ
What was aap Implantate AG’s price range in the past 12 months?
aap Implantate AG lowest stock price was €1.26 and its highest was €2.34 in the past 12 months.
What is aap Implantate AG’s market cap?
aap Implantate AG’s market cap is €23.11M.
When is aap Implantate AG’s upcoming earnings report date?
aap Implantate AG’s upcoming earnings report date is Aug 17, 2026 which is in 25 days.
How were aap Implantate AG’s earnings last quarter?
aap Implantate AG released its earnings results on Apr 30, 2026. The company reported -€0.116 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.116.
Is aap Implantate AG overvalued?
According to Wall Street analysts aap Implantate AG’s price is currently Overvalued.
Does aap Implantate AG pay dividends?
aap Implantate AG does not currently pay dividends.
What is aap Implantate AG’s EPS estimate?
aap Implantate AG’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does aap Implantate AG have?
aap Implantate AG has 14,716,976 shares outstanding.
What happened to aap Implantate AG’s price movement after its last earnings report?
aap Implantate AG reported an EPS of -€0.116 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.913%.
Which hedge fund is a major shareholder of aap Implantate AG?
Currently, no hedge funds are holding shares in DE:AAQ1
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aap Implantate Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Company Description
aap Implantate AG
Operating as a medical technology firm, aap Implantate AG specializes in the development, manufacturing, and commercialization of orthopedic trauma devices. The company's market presence spans Germany, the United States, and various international regions. Its primary offerings feature LOQTEQ, an advanced anatomical plating system crucial for fracture treatment, in addition to a diverse selection of cannulated screws, conventional plates, and standard screws. Products are distributed under the 'aap' brand, reaching customers directly, including hospitals, purchasing syndicates, and hospital groups, as well as indirectly via its network of distributors. aap Implantate AG was founded in 1990 and maintains its corporate headquarters in Berlin, Germany.
Technical Analysis
Carl Zeiss Meditec
―
Eckert & Ziegler Strahlen und Medizintechnik
―
Geratherm Medical
―
MagForce AG
―
elexxion AG
―